Impact of personalized pharmacokinetics-guided prophylaxis using standard half-life factor VIII in patients with hemophilia A
DOI:
https://doi.org/10.69898/jhtm.35.2025.274950Keywords:
Hemophilia A, Personalized, Pharmacokinetics, Standard Half-Life Factor VIIIAbstract
Abstract
Introduction: Patients with Hemophilia A (HA) are at risk of severe bleeding and joint damage, which can lead to disability. Nonpharmacokinetic (PK)-guided prophylaxis treatment may not be suitable for all patients, as it does not involve personalized prophylaxis tailored to their activity levels. Objective: This study aimed to evaluate the clinical impact of PK-guided prophylaxis using standard half-life factor VIII (SHL FVIII) based on activity risk levels in patients with severe phenotype HA. Material and method: This retrospective and prospective cohort study compared data from the same group of patients receiving prophylactic treatment at Naradhiwasrajanagarindra Hospital between September 2023 and August 2024. Data from 6 months before and 6 months after the implementation of personalized PK-guided prophylaxis, combined with activity risk level design and digital diary application monitoring, were compared. Collected data included the annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), Hemophilia Joint Health Score (HJHS), Functional Independence Score in Hemophilia (FISH) and weekly consumption of SHL FVIII. Result: The study included 12 participants (mean age ± standard deviation [SD]: 16 ± 6.95 years). The results showed statistically significant reductions in ABR, AJBR, and HJHS (P = 0.005, 0.007, and 0.002, respectively). The median (interquartile range [IQR])FISH score increased from 26.50 (24 – 28.5) to 28 (26 – 29.75) (P = 0.002), while weekly SHL FVIII consumption did not significantly increase. Conclusion: Personalized treatment adjustments using PK data SHL FVIII and digital tools effectively improved treatment outcomes and supported patient activities.
Downloads
References
Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia. 3rd ed. Haemophilia. 2020;26:1-158.
Kempton CL. Prophylaxis in hemophilia: how much is enough? Blood. 2021;137:1709-11.
Iorio A. Using pharmacokinetics to individualize hemophilia therapy. Am Soc Hematol. 2017;130:595-604.
Croteau SE, Wheeler AP, Khan O, Haley KM, Borst AJ, Lattimore S. Pharmacokinetic-tailored approach to hemophilia prophylaxis: medical decision making and outcomes. Res Pract Thromb Haemost. 2020;4:326-33.
Lim MY. How do we optimally utilize factor concentrates in persons with hemophilia? Am Soc Hematol. 2021;:206-14.
Wang Y, Yang Q, Zheng L, Wang X, Jiang W, Lu L, et al. Efficacy of individualized preventive treatment of patients with severe hemophilia A guided by multiple clinical parameters and pharmacokinetics. Acta Haematol. 2022;145:354-61.
Goedhart TMHJ, Bukkems LH, Zwaan CM, Mathot RAA, Cnossen MH. Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice. Blood Adv. 2021;5:4314-25.
Banchev A, Goldmann G, Marquardt N, Klein C, Horneff S, Langenkemp R, et al. Impact of telemedicine tools on record keeping and compliance in haemophilia care. Hamostaseologie. 2019;39:347-54.
Mondorf W, Eichler H, Fischer R, Holstein K, Klamroth R, Nimtz-Talaska A, et al. Smart Medication, an electronic diary for surveillance of haemophilia home care and optimization of resource distribution. Hamostaseologie. 2019;39:339-46.
Leone JR. Utility of a wireless, handheld monitoring system in the management of hemophilia patients. Comput Inform Nurs. 2011;29:521-2.
Cuesta-Barriuso R, Lopez-Pina JA, Nieto-Munuera J, Sagarra-Valls G, Panisello-Royo JM, Torres-Ortuno A. Effectiveness of the Medtep Hemophilia online platform for adherence to prophylactic treatment in haemophilia patients: results from a 1-year observational study. Haemophilia. 2018;24:452-9.
Park Y-S, Yoo K-Y, Park SK, Hwang T, Jung A, Choi EJ. Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review. Blood Res. 2024;59:29.
Mingot-Castellano ME, Parra R, Núñez R, Martorell M. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT®. Haemophilia. 2018;24:338-43.
Antonazzo IC, Cortesi PA, Zanon E, Pasca S, Morfini M, Santoro C. Personalized prophylaxis with myPKFiTCE: A real-world cost-effectiveness analysis in haemophilia A patients. Medicina. 2024;60:1-10.
Pasca S, Zanon E. Savings without changing: How to use the MyPKfit® device to improve treatment strategies in a cohort of patients with haemophilia A. Thromb Res. 2019;183:1-3.
Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 2017;23:170-9.
Ribeiro T, Abad A, Feldman BM. Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1. Haemostasis. 2019;3:405-11.
Choudhary R, Sharma P, Nigam RK, Malik R. Functional Independence Score in haemophilia: A hospital-based observation study in a tertiary care center in central India. J Evid Based Med. 2019;6:2702-5.
Ferri Grazzi E, Sun SX, Burke T, O'Hara J. The impact of pharmacokinetic-guided prophylaxis on clinical outcomes and healthcare resource utilization in hemophilia A patients: real-world evidence from the CHESS II study. J Blood Med. 2022;13:505-16.
Young G, Callaghan MU, Balasa V, Soni A, Ahuja S, Roberts JC. Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe haemophilia A. Haemophilia. 2023;29:1234-42.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
